GTR 78225874
Bids Are Invited For Regular Acquisition Of Bromocryptine (Mesylate) Tablet 2.5 Mg And Others, In A Price Registration System, To Meet The Needs Of The Df Health Department, According To Specifications And Quantities Contained In Annex I Of The Notice.
ICB — International Competitive Bid
Closed
South America
Tender Information
GTR Reference
78225874
Tendering Authority
Subscribe to view
Tender No
90040/2024
Financer Name
Self-Funded
Work Title
Bids Are Invited For Regular Acquisition Of Bromocryptine (Mesylate) Tablet 2.5 Mg And Others, In A Price Registration System, To Meet The Needs Of The Df Health Department, According To Specifications And Quantities Contained In Annex I Of The Notice.
Bid Type
ICB — International Competitive Bid
Country
Subscribe to view
Geographical Region
South America
Political Region
BRIC,G20
Last Date of Bid Submission
26-03-2024
Closed
Work Detail
Regular Acquisition Of Bromocryptine (Mesylate) Tablet 2.5 Mg And Others, In A Price Registration System, To Meet The Needs Of The Df Health Department, According To Specifications And Quantities Contained In Annex I Of The Notice.. Bromocriptine Mesylate,Cabergoline,Cyproterone Acetate,Estriol,Finasteride,Medroxyprogesterone Acetate,Methylergometrine Maleate,Metronidazole,Metronidazole,Misoprostol,Misoprostol,Misoprostol,Oxybutynin Hydrochloride,Oxybutynin Hydrochloride,Oxybutynin Hydrochloride,Oxybutynin Chlor Hydrate,Progesterone,Progesterone,Raloxifene Hydrochloride,Sildenafil ,Sildenafil,Tadalafil,Tadalafil,Testosterone,Testosterone
Key Value
Tender Value
Ref. Document
Tender Documents
Global Tender Document
732821ec-6e65-4ce2-a9e0-94c2819db802.html
Attachments
Additional Details Available on Click
- Tendering Authority
- Publication Document (Tender Document / Tender Notice)
Disclaimer
We take all possible care for accurate & authentic tender information. However, users are requested to refer to the original Tender Notice / Tender Document published by the Tender Issuing Agency before taking any decision regarding this tender.